// App-Quantinova.ai

PO1624 : ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1)

Researchers

Presenter

  • Michael Mini

Principal Investigators

  • Deschnes Georges

  • Cochat Pierre

  • Magen Daniella

  • van't Hoff William

  • Sas DavidJ

  • Schalk Gesa

  • Shasha-Lavsky Hadas

  • Hayes WesleyNathan

  • Bae Kyounghwa

  • Seddighzadeh Ali

  • Garg Pushkal

  • Vaishnaw Akshay

  • McGregor Tracy

  • Fujita Kenji

  • Frishberg Yaacov

Medical Centers

  • Pediatrics, Texas Childrens Hospital, Baylor College of Medicine, Houston, Texas, United States

  • Hosp Robert Debre, Paris, France

  • Centre for Rare Renal Diseases & Inserm Pediatric Clinical Investigation Centre – Hospices Civils de Lyon and Université de Lyon Lyon France

  • Rambam Health Care Campus, Haifa, Israel

  • Great Ormand Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

  • Mayo Clinic Minnesota Rochester Minnesota United States

  • University of Bonn Rheinische Friedrich-Wilhelms-Universitat Bonn Bonn Nordrhein-Westfalen Bonn Nordrhein-Westfalen Germany

  • Galilee Medical Center Nahariya Israel Nahariya Israel

  • Alnylam Pharmaceuticals Cambridge Massachusetts United States

  • Shaare Zedek Medical Center, Jerusalem, Israel

Locations

  • United States

  • France

  • Israel

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

Disease

  • Primary hyperoxaluria type 1

Biomarkers

  • Creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved